Samsung Biologics to provide end-to-end mRNA vaccine manufacturing

Samsung Biologics to provide end-to-end mRNA vaccine manufacturing

Source: 
Biopharma Reporter
snippet: 

Samsung Biologics will add mRNA vaccine drug substance production capability to its facility in South Korea, aiming to provide end-to-end mRNA vaccine manufacturing services.